Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - estradiol valerate (in brown tablet); estradiol valerate (in white tablet); norgestrel (in brown tablet) - tablet, sugar coated - 2 mg - estradiol valerate (in brown tablet) 2 mg; estradiol valerate (in white tablet) 2 mg; norgestrel (in brown tablet) 0.5 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - entacapone 200 milligram/1 tablet, levodopa 200 milligram/1 tablet, carbidopa 50 milligram/1 tablet - 200 milligram/1 tablet, 200 milligram/1 tablet, 50 milligram/1 tablet

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 17.857 mg (equivalent: darifenacin, qty 15 mg) - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000; iron oxide yellow; iron oxide red - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 8.929 mg (equivalent: darifenacin, qty 7.5 mg) - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000 - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; iron oxide yellow; purified talc; macrogol 4000; iron oxide red; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 8000; magnesium stearate; hypromellose; colloidal anhydrous silica - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - methylprednisolone, quantity: 4 mg - tablet - excipient ingredients: gelatin; maize starch; magnesium stearate; purified talc; lactose monohydrate - yonsa mpred is indicated for the treatment of patients with: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or; patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or; patients with mcrpc who have received prior chemotherapy containing a taxane.

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.